Skip to main content

Table 1 Patients’ clinicopathological information

From: NEK7 promotes gastric cancer progression as a cell proliferation regulator

Characters

NEK7-high

NEK7-low

P-value

Status

   

 Alive

103

125

 

 Dead

85

62

0.022

Age

  

 Mean (SD)

65.7 (10.3)

65.9 (11.1)

 Median [MIN, MAX]

67 [35, 90]

67.5 [39, 90]

0.856

Gender

   

 Female

71

63

 

 Male

117

124

0.474

Race

   

 Asian

28

46

 

 Black

6

5

 

 White

130

108

 

 Islander

 

1

0.04

pT_stage

   

 T1

1

4

 

 T1b

2

10

 

 T2

22

36

 

 T2a

6

3

 

 T2b

6

7

 

 T3

78

90

 

 T4

18

12

 

 T4a

33

13

 

 T4b

14

10

 

 TX

8

  

 T1a

 

2

0.003

pN_stage

   

 N0

50

61

 

 N1

44

53

 

 N2

42

33

 

 N3

12

14

 

 N3a

26

16

 

 N3b

1

5

 

 NX

12

4

0.058

pM_stage

   

 M0

165

165

 

 M1

12

13

 

 MX

11

9

0.888

pTNM_stage

   

 IA

3

11

 

 IB

19

18

 

 II

12

15

 

 IIA

11

24

 

 IIB

27

22

 

 IIIA

34

26

 

 IIIB

24

28

 

 IIIC

24

11

 

 IV

19

19

 

 I

 

2

 

 III

 

3

0.036

Grade

   

 G1

5

5

 

 G2

56

81

 

 G3

120

99

 

 GX

7

2

0.025

New_tumor_event_type

   

 Metastasis

31

23

 

 Metastasis: recurrence

3

1

 

 Primary

2

1

 

 Recurrence

17

12

 

 Recurrence: primary

 

1

0.907

Radiation_therapy

   

 Non-radiation

61

84

 

 Radiation

25

19

0.122

History_of_neoadjuvant_treatment

   

 No neoadjuvant

188

187

 

Therapy_type

   

 Ancillary: chemotherapy

19

13

 

 Chemotherapy

63

65

 

 Chemotherapy: other. Specify in notes

1

  

 Chemotherapy:

 

1

 

 Chemotherapy: targeted molecular therapy

 

1

0.406